Form 8-K - Current report:
SEC Accession No. 0000886163-25-000003
Filing Date
2025-02-25
Accepted
2025-02-25 16:02:36
Documents
16
Period of Report
2025-02-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lgnd-20250224.htm   iXBRL 8-K 33218
2 EX-99.1 exhibit991_castlecreekdeal.htm EX-99.1 18066
6 image_0.jpg GRAPHIC 80691
7 image_1.jpg GRAPHIC 732944
  Complete submission text file 0000886163-25-000003.txt   1301399

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20250224.xsd EX-101.SCH 1792
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20250224_lab.xml EX-101.LAB 22783
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20250224_pre.xml EX-101.PRE 13053
18 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20250224_htm.xml XML 2728
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 25662916
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)